Promising Phase II results for non-opioid pain drug

In Düsseldorf, Algiax Pharmaceuticals is working on a novel analgesic which could provide an effective alternative to opioids.

The firm has just released Phase IIa results showing that its lead candidate, AP-325, could provide rapid and lasting pain relief for patients with chronic neuropathic pain. The small molecule also demonstrated a strong safety profile.

Algiax said the drug achieved clinically meaningful pain reduction within two weeks. More than 25% of treated patients reported at least a 50% reduction in pain, compared to 11% in the placebo group.